Drugs / INS316
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01381666 | Jan 2003 → Apr 2004 | interstitial lung disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00008255 | Aug 2000 → May 2004 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00033527 | — | lung cancer | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INS316 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00033527 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic Utility of INS316” NCT01381666 ↗ |
| Route | Inhaled | “Patients receive INS316 by inhalation via a nebulizer” NCT00008255 ↗ |